& Abstract: We sought to assess the extent to which pain relief in chronic back and leg pain (CBLP) following spinal cord stimulation (SCS) is influenced by patient-related factors, including pain location, and technology factors. A number of electronic databases were searched with citation searching of included papers and recent systematic reviews. All study designs were included. The primary outcome was pain relief following SCS, we also sought pain score (pre-and post-SCS). Multiple predictive factors were examined: location of pain, history of back surgery, initial level of pain, litigation/worker's compensation, age, gender, duration of pain, duration of follow-up, publication year, continent of data collection, study design, quality score, method of SCS lead implant, and type of SCS lead. Betweenstudy association in predictive factors and pain relief were assessed by meta-regression. Seventy-four studies (N = 3,025 patients with CBLP) met the inclusion criteria; 63 reported data to allow inclusion in a quantitative analysis. Evidence of substantial statistical heterogeneity (P < 0.0001) in level of pain relief following SCS was noted. The mean level of pain relief across studies was 58% (95% CI: 53% to 64%, random effects) at an average follow-up of 24 months. Multivariable meta-regression analysis showed no predictive patient or technology factors. SCS was effective in reducing pain irrespective of the location of CBLP. This review supports SCS as an effective pain relieving treatment for CBLP with predominant leg pain with or without a prior history of back surgery. Randomized controlled trials need to confirm the effectiveness and cost-effectiveness of SCS in the CLBP population with predominant low back pain. &
medical management and an alternative to a further operation in individuals with chronic back and leg pain (CBLP), whom have undergone previous back surgery, so-called "failed back surgery syndrome" (FBSS). 1, 2 Through improved pain relief, SCS provides important enhancement to the functionality and health-related quality of life of those with CBLP. 3 The National
Institute for Health and Care Excellence (NICE) in the United Kingdom recently reviewed these trials and evidence of cost-effectiveness. [4] [5] [6] On the basis of their review, NICE recommended SCS as a treatment for patients suffering from refractory chronic neuropathic pain conditions, including CBLP. 7 Chronic back and leg pain (CBLP) represents a poorly defined group of pain conditions, ranging from chronic low back (axial) pain to persistent hip, buttock and leg (radicular) pain syndromes, but often consists of a combination of both. 8 CBLP consists of both back and leg pain and is differentiated here from CLBP. Greater success of SCS in treatment of radicular pain has been reported than with axial low back pain; 9,10 however, both randomized controlled trials of SCS in FBSS recruited only those individuals who presented with predominant leg pain, excluding those with a chief complaint of axial pain exceeding radicular pain. 1,2 A meta-analysis of cases series in CBLP noted a substantial level of heterogeneity in the level of pain relief following SCS. 11 Although the authors of this analysis examined a number of predictive factors that may influence the differing degree of pain relief, they did not consider pain location, that is, whether pain was predominantly leg or back in origin. With the continued technological development of SCS (eg, number of electrodes, electrode configurations, programming options), there is a growing interest in understanding how these innovations impact on the level of pain relief experienced by patients with CBLP. [12] [13] [14] The aim of this study was to examine the predictive value of patient-related factors, including leg versus back pain location and whether patients have undergone previous back surgery (FBSS), as well as SCS technologyrelated factors.
METHODS
This review was carried out and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 15 
Literature Searches
Studies were initially identified from a previous systematic review undertaken by some of the authors (RST, RJT). 11 Portal and ClinicalTrials.gov) were searched for information on current or recently completed studies. Citation lists of included papers and recent systematic reviews were checked for additional references. [16] [17] [18] Issues of the journal "Neuromodulation" were hand searched up to September 2012. Two reviewers (RST and RJT) independently scanned all the titles and abstracts and identified potentially relevant articles to be retrieved. Where there was uncertainty, full-text copies of papers were obtained.
Inclusion and Exclusion Criteria
Studies were considered eligible if they fulfilled the following criteria:
Population-adults with CBLP, who present with predominant leg pain, predominant back pain, or mixed leg and back pain, irrespective of whether they have undergone prior back surgery or not. Intervention-SCS. Comparator-none or any comparative therapy. Outcomes-our primary outcome was the proportion of patients achieving pain relief. Pain outcome reported as a continuous score was a secondary outcome.
Studies were excluded on the basis of: combining SCS with other interventional procedures, such as intrathecal drug delivery or other types of neurostimulation, reporting of only technical outcomes (ie, device settings or stimulation protocols or parasthesia coverage) and no pain-related outcomes, mixed case series (ie, recruit patients from a number of indication groups) where only aggregated results were reported, single case reports or case reports, studies published as abstracts only; and non-English language publications.
Data Extraction
The following categories of information were extracted from included studies: study population baseline characteristics (eg, age, gender, duration and location of pain); (2) SCS intervention (ie, use of test screen, type of internal implant generator, lead and placement method, stimulation parameters); study characteristics (eg, study design, country of publication, length of follow-up); and outcome results. Where studies assessed outcomes at more than one follow-up, we extracted the latest follow-up.
Study Quality Assessment
In accord with a previous systematic review, 11 the following five factors were considered in the assessment of study quality: (1) prospective study design; (2) consecutive patient sampling; (3) explicit statement of patient inclusion/exclusion criteria; (4) losses to followup; and (5) blinded/independent assessment of outcome. Data extraction and quality assessment were undertaken by a single reviewer (RJT) using a standardized form and verified by a second reviewer (RST). Any disagreements were resolved by consensus.
Data Synthesis and Analysis
Quantitative data analysis focused on the primary outcome, that is, the proportion of patients experiencing pain relief following SCS. In the case of controlled studies, only the SCS arm was used. For each study, pain relief was expressed as a percentage and the 95% confidence interval calculated (based on an exact binomial distribution). Results were pooled across studies using meta-analysis methods using the inverse variance approach. 19, 20 Heterogeneity among studies was first explored qualitatively (by comparison of the characteristics of included studies) and quantitatively (using the v 2 test of heterogeneity and I 2 statistic). Given that both the level of clinical and statistical heterogeneity were seen (ie, v 2 test of heterogeneity < 0.05 and I 2 statistic > 50%), the DerSimonian Laird random-effects method was used to pool studies. 21, 22 Rather than simply calculate a single overall pooled estimate of the effectiveness of SCS, the primary aim of analysis was to explore heterogeneity and assess the patient and technology-related factors that were associated with SCS pain relief. The funnel plot was examined and Egger et al.'s test calculated to examine the likely presence of publication bias and small-study effect. 23 A "between-study" analysis used meta-regression to examine the influence of the following prespecified study level factors: initial level of pain (mean pain score) type of CBLP (predominant back pain vs. predominant leg pain vs. mixed leg and back pain; CBLP with history of back pain surgery vs. CBLP with no history of back pain surgery); age (mean); gender (% male); duration of pain (mean); duration of follow-up (mean); litigation/worker's compensation; year of publication; continent of data collection (North America vs. Europe vs. other); study setting (single vs. multicenter); SCS intervention (surgical vs. percutaneous leads, quadripolar vs. octapolar vs.16-contacts); study design (RCT or non-RCT vs. case series); and quality score. These factors were assessed in both a univariable and multivariable model with P value adjustment for multiple testing. 24 Studies reporting continuous pain scores (either as visual analog scale [VAS] or numerical rating scale [NRS]) were separately pooled using meta-analysis as pre-and post-SCS change scores. In accord with recommended methods for pooling pain outcomes, where necessary, pain scores were transformed, so all studies were expressed on a 0-10 scale. 11, 25, 26 Where not reported, standard deviation for change was calculated using pre-and post-SCS standard deviations (assuming a within-study correlation coefficient of 0.9).
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A number of studies reported the association between patient-related and technology-related factors and SCS pain relief. The results of these "within-study" analyses were tabulated and reported descriptively. All quantitative analyses were performed using STATA v.11.1 (Stata Corp., College Station, TX, U.S.A.).
RESULTS

Identification and Selection of Studies
Our previous systematic review included a total of 78 studies of which 21 studies were judged not to meet the revised inclusion criteria of this present review. 11 The main reasons for exclusion were non-English language and abstract only publications. The electronic searches for this updated review yielded a total of 992 titles, of which 18 new studies were included. Therefore, a total of 74 studies (77 publications) were included, of which 68 were case series, four were RCTs, and two were comparative studies using a nonrandomized design. The selection process is summarized in Figure 1 (citations of studies included and excluded on the basis of full paper review are listed in Appendix S2). The characteristics of the included studies are summarized in Table 1 .
Study Quality
Details of study methodology were generally poorly reported, therefore, limiting our ability to assess study quality (see Table 2 ). Only four studies fulfilled all five criteria, that is, used a prospective design, recruited consecutive or all eligible patients, provided an explicit description of inclusion and exclusion criteria, blinded outcome assessment or used a third party assessor, and reported a loss to follow of 20% or less [lvi, xxxviii, lxix, lxx]. The overall quality of studies was in general relatively poor with a median quality score of 2 out of a potential maximum score of 5. There was evidence of an increase in quality score over time (ie, median quality score of studies published in [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] statistic: 85%). Overall, 58% (95% confidence interval (CI): 53% to 64%, random effects) of patients with CBLP achieved pain relief (see Figure 2 ). Studies used a range of definitions of pain relief that included objective cut-offs (eg, ≥ 50% reduction in pain) and subjective cut-offs (eg, "satisfactory", "good" or "excellent" pain relief). However, the level of pain relief with SCS appeared consistent when limited to those 32 studies that used an objective definition (53%, 95% CI: 47% to 59%, random effects).
There was evidence of small-study bias and potential publication bias as evidenced by funnel plot asymmetry (see Figure S1 ) and a significant Egger test (P = 0.003).
Eleven studies (12 comparisons) reported pain score before and after SCS data appropriately to allow metaanalysis [ii, lvii, lviii, lix, lx, lxi, lxv, lxix, xliii, lxxv, lxxvii]. There was evidence of significant statistical heterogeneity (v 2 statistic: 237.8, P < 0.0001, I 2 statistic: 95%) across studies. The mean reduction in pain score (on 0-10 scale) with SCS across studies was À3.3 (95% CI: À3.9 to À2.7, random effects; see Figure 3 ). There were insufficient studies to examine the association between patient and device-related factors and the change in pain score with SCS.
Meta-Regression and Stratified Meta-analysis
In univariable meta-regression analysis, the only study level factor to be associated with level of SCS pain relief was the mean duration of pain (P = 0.011; see Table 3 ). An increasing mean duration of pain across studies was associated with a reduction in the level of SCS pain relief -each 12-month increase in the duration of pain reduced the level of pain relief by~2.0% (see Figure 4) . Figure 5 shows a meta-analysis stratified by the location of CBLP pain. There appeared a higher level of pain relief with studies in individuals with predominantly back pain compared with studies in those with predominantly leg pain (see Figure 5 ). However, the number of studies contributing data to this analysis was small [ii, xvi, lxx], and no significant statistical association with pain relief and the location of CBLP was seen in either univariable or multivariable meta-regression. In multivariable analysis, no study-or patient-or technology-related characteristics were seen to be significant predictors of pain relief following SCS (see Table 3 ). Richardson (1982) Kumar (2007) Leclercq (1982) Kumpulainen (1986) Vonhogen (2011) Kavar (2000) Barolat ( Ray (1975) Probst (1990) Kumar (1986) DeLaPorte (1983) Sears (2011) Hoppenstein (1975) Kim (1994) Leveque (2001) Devulder ( Clark (1975) Kay (2001) Van der Kleft (1994)
Waisbrod (1985) DeVos (2012) Pineda (1975) DeLaPorte (1993) Hassenbusch (1995) Burchiel (1995) Dario (2001) Devulder (1990) Siegfeld (1982) Barolat (2001 Figure 2 . Meta-analysis of pain relief following SCS.
Within-study Analysis
Back vs. Leg Pain Outcome. Ten SCS studies reported both back and pain leg outcomes following SCS in the same individuals [ii, lix, lx, lxv, lxvii, lxx, xxxix, lxxiii, lxxvi, lxvii, lxx, xxxix, lxxiii, lxxvi, lii] (see Table 4 ). In the four studies in which pain was predominantly leg, three reported a higher level of pain relief for the leg than the back [lxv, xxxiv, lxx]. Device-related Factors. Seven studies examined the association between device-related aspects of SCS and pain relief [xi, xxi, xxvii, lxvii, xxxvii, lxix, xli] (see Table 5 ). reported differences between SCS devices in "time to failure"; a composite outcome taking into account trial stimulation failure, device complication, and loss of pain relief Table 6 ). 
DISCUSSION
This systematic review of evidence base on pain relief following SCS quantifies the association between the level of pain relief and patient and technology-related factors. Our review included 74 studies in a total of 3,025 individuals with CBLP, the majority of which were post back surgery (ie, patients with FBSS). We found a substantial number of individuals experience important levels of pain reduction following SCS, that is, 53% (95% CI: 47% to 60%) achieving an equivalent of 50% more pain relief at a mean follow-up of 24 months. This is supported by a magnitude of reduction in pain score (on 0-10 scale) with SCS studies of À3.3 (95% CI: À3.9 to À2.7) that indicates a clinically important change (ie, a change of 2 or more units on 0-10 scale 27, 28 ). Although there was considerable heterogeneity across studies, we found no strong evidence that pain relief with SCS was limited to particular patients with CBLP subgroups. The one exception was the duration of pain, that is, those studies with the longest mean duration of pain reported a smaller magnitude of pain relief following SCS. However, we need to be cautious in this interpretation as this study level association was not seen in multivariable analysis, that is, adjusting for other study level characteristics. Two studies have shown that patients with FBSS receiving a surgical lead placement by laminectomy have superior analgesic outcomes compared with those who received a percutaneous lead placement. 13, 29 It is believed that SCS may be a more successful therapy for CBLP in those who present with pain predominantly in the legs than the low back.
12-14 While we sought to quantitatively explore the association between the level of SCS pain relief and the location of pain, because of the quality of reporting of the majority of included studies (few studies reported either the precise details of the location of pain pre-SCS, the pain outcome in both leg and back post-SCS), we were only able to partially do so. Although contemporary studies are better, only a minority of studies provide sufficient description of the entry criteria and assessment of participants to be able to reliably determine the location of their CBLP. Additionally, few studies have reported data on the level of pain relief in both the legs and the back. Accepting these limitations, SCS appears to be effective in reducing CBLP irrespective of back or leg pain location. Although increasing in the number, fewer SCS studies to date have reported outcomes of SCS in predominantly back pain populations. We identified no 
Comparison with Previous Reviews
The level of pain relief seen in this update review is consistent (ie, the 95% CIs overlap) with the findings of our 2005 meta-analysis-62% (95% CI: 56% to 69%) achieving an equivalent of 50% or more pain relief following SCS at a mean follow-up of 26 months. 11 In this present study, we only found the duration of pain to be predictive of the level of pain relief following SCS, while the previous meta-analysis identified a number of predictors (ie, duration of study follow-up, type of pain [CBLP vs. FBSS] and study setting [single vs. multicenter]). This difference probably reflects the somewhat different evidence base between the two analyses-we excluded some studies from the previous review (eg, abstracts only, mixed case series that did not specifically report outcomes in those with CBLP) and a number of studies, published since, have been included in this review. Previous systematic reviews of SCS for CBLP have not formally quantified the difference in level of pain relief with SCS according to the location of CBLP or whether pain assessment was specific to either the legs or back or aspects of SCS technological innovation. 5, 11, 17, 18, 30 However, a number of these issues have been qualitatively reviewed in the "Pain Practice Parameters for the Use of Spinal Cord Stimulation in the Treatment of Chronic Neuropathic Pain" report.
9 This report gave a "level B" recommendation (ie, uncertain validity) that pain is most likely to be treated successfully by SCS if: "The pain location is radicular or radiating than axial in distribution (predominant low back pain is more difficult to treat)….".
Strengths and Limitations
We made every effort to reduce potential bias in this review. We used comprehensive electronic searches, including the searching of reference lists of included studies and previous reviews. However, we did find evidence of small-study bias that may reflect some level of publication bias. By including only studies that reported pain outcomes in CBLP individuals, we sought to minimize confounding due to the effects of SCS on other indications. We found several potential biases in the included studies: methodological details were often poorly reported with respect to the use of prospective Generic pain* Pre-SCS: mean 9.4 Post-SCS: mean 4.7,
Back pain* Pre-SCS: mean 9.7 Post-SCS: mean 4.6,
Leg pain* Pre-SCS: mean 9.5 Post-SCS: mean 3.6,
"Comparable VAS changes were reported at the interim follow-up for global, back and leg pain"
*VAS (0-10) pain score design, population selection, and independent outcome blinding. Therefore, there was potential for selection and assessment bias. As outlined above, the principle limitation of this study was the failure by more than half of the included studies to report sufficient details to enable us to assess the factors that may be predictive of pain relief, including the precise location of pain. CBLP and FBSS are heterogeneous descriptors; identification of specific pain predictors can allow stratification of this broad group of patients and, thereby, the optimization of therapy. Another limitation is the risk of ecological fallacy with meta-regression. An association between pain relief and patient and technology factors at a study level may not reflect such an association within a study and, therefore, at the level of individual with CBLP. To overcome such criticism, we used multivariable analysis; therefore, adjusting for what might be potential confounders. Additionally, we have reported within-study analyses to check whether they were consistent with our meta-regression analysis.
Implications
A number of international clinical guidelines currently recommend SCS as evidence-based treatment for the management of CBLP following back surgery (ie, FBSS). 7, 9, 30 The PROCESS trial reported that 24%
(n = 51) of 214 preselected individuals with FBSS did not enter the trial specifically because of their predominant lower back pain component. 1 Targeting and the effective management of axial back pain has become a focus for recent technological innovation in neuromodulation. This has seen the development and use of multipolar SCS electrodes, hybrid peripheral nerve stimulation systems, and alternative stimulation techniques. 12 Well-conducted trials, using contemporary technological advances in neurostimulation, in individuals with predominant back pain, are needed. Future publications need to better report inclusion and screening processes in sufficient detail to allow a better understanding of factors that may predict the success of SCS, including details on the technology used, the precise location of pain location, pain duration, and level of opioid prior to therapy. In addition to the assessment of patient-related outcomes, such as healthrelated quality of life and functional capacity, studies should collect pain outcomes in both the leg and back, to enable better understanding of the target of neurostimulation. We are aware of two randomized trials of SCS currently being undertaken in back pain. The first is a multicenter French study that aims to compare the analgesic efficacy of mono-column SCS (using longitudinal and transverse electric stimulation) versus mono-column SCS (using axial stimulation, represented by quadripolar or octopolar lead; ESTIMET, NCT01628237). A total of 115 patients with lumbar pain will be randomly allocated to each of the SCS approaches and their leg and back pain, function, level of depression, healthrelated quality, and costs at 6-and 12-month postrandomization. Second, a multi-country randomized trial (PROMISE, NCT01697358) is ongoing. Two hundred and twelve patients with FBSS presenting with predominant back pain will be randomized to SCS using a tripolar 16-contact lead plus optimal medical management as compared to optimal medical management alone in a postoperative CBLP population with predominant back pain. This parallel designed trial aims to assess outcomes at 6 to 24-months including leg and back pain relief, health-related quality of life, functional capacity, and costs.
CONCLUSIONS
This systematic review and meta-analysis supports SCS as an effective pain relieving treatment for CBLP in patients with or without a prior history of back surgery and presenting as predominantly leg pain. Randomized controlled trials are needed to confirm the effectiveness and cost-effectiveness of SCS in the CBLP population with predominant low back pain and examine patient and technology-related factors that may be predictive of SCS success.
